malignant hematologic disorders
Conditions
Interventions
intra-bone injectioin:Intra-bone injection of mononuclear cells from bone marrow
transfusion by venous:transfuse the hematopietic cells by venous
Sponsors
Central South University Xiangya Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: At the age of 14 years old to 65 years old (14 years old and 65 years old); According to the classification standard of diagnosis of malignant diseases of the blood system in 2008 edition of WHO, MDS and leukemia patients; With hematopoietic stem cell transplantation indications but no HLA matched sibling or unrelated donor transplantation; or the condition requirements as soon as possible without looking HLA haploidentical donor opportunity; The last time to start of chemotherapy into the group of at least 30 days; the last time to the end of chemotherapy into the group of at least 10 days; The specificity of HCT prognostic index (HCT-CT) of less than 4 (including 4); Cardiac ejection fraction greater than 50% (including 50%); The total bilirubin level in the normal 2 times the upper limit of the following; alanine aminotransferase and aspartate aminotransferase levels in the normal 3 times the upper limit of the following; Diffusion capacity for carbon monoxide (according to hemoglobin level adjusted) greater than 40% (including 40%); forced expiratory volume in one second more than 50% (including 50%); Creatinine clearance rate greater than 50ml/min; Signed informed consent.
Exclusion criteria
Exclusion criteria: Symptoms of coronary heart disease; In group 4 weeks before the memory in the central nervous system leukemia (primitive cells in cerebrospinal fluid of positive); The fitness score less than 70 points; Viruses, bacteria and fungi uncontrolled infection (Advances in antifungal therapy process still condition); HIV seropositive; Other system malignant tumor history; Pregnant and lactating women; Do not agree in the trial period and male and female contraception;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| survival time;disease free survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Death associated with transplant;incidence and degree of graft-versus-host disease; | — |
Countries
China
Contacts
Public ContactBin Fu
Outcome results
None listed